人参皂苷Rg3与顺铂对荷卵巢癌裸鼠免疫功能及肿瘤相关蛋白的影响  

Effect of Ginsenoside Rg3 and Cisplatin on Immunity and Tumor Related Proteins in Nude Mice Bearing Ovarian Cancer

作　　者：陈鲁[1] 屠珏[2] 张英丽[1] 

机构地区：[1]浙江省肿瘤医院,浙江杭州310022 [2]浙江中医药大学动物实验研究中心,浙江杭州310053

出　　处：《肿瘤学杂志》2014年第11期914-919,共6页Journal of Chinese Oncology

基　　金：浙江省中医药科技计划资助项目(2011ZA015)

摘　　要：[目的]观察人参皂苷Rg3联合顺铂对荷高转移人卵巢癌细胞系HO-8910PM转移瘤裸鼠白细胞介素-2(IL-2)、干扰素-γ(INF-γ)及nm23、血管内皮生长因子(VEGF)及增殖细胞核抗原(PCNA)的影响。[方法]移植瘤裸鼠随机分成6组腹腔给药:荷瘤空白对照组(A组);不同Rg3浓度药物组:2.5mg/kg(B组)、5mg/kg(C组)和10mg/kg(D组);Rg3和顺铂联用组(E组)以及顺铂阳性对照组(F组)。分别测定各组裸鼠转移瘤体积变化、IL-2、INF-γ、nm23、VEGF及PCNA的变化情况。[结果]与A组比较,E组(P<0.05)和F组(P<0.01)小鼠血清中IL-2、INF-γ含量均能显著降低;B(P<0.05)、C、D和E(P<0.01)组小鼠移植瘤组织nm23的表达均增强。Rg3给药后,小鼠移植瘤组织VEGF、PCNA表达均呈下降趋势。[结论]人参皂苷Rg3和顺铂联用具有协同抗肿瘤及减毒的作用。Rg3可能通过增强nm23的表达,使VEGF及PCNA表达呈下降趋势等多途径产生抗肿瘤作用。[Purpose] To investigate the effects of ginsengside Rg3 combined with cisplatin on the expression of IL-2, INF-γ, nm23, vascular endothelial growth factor （VEGF） and proliferating cell nuclear antigen （PCNA） in nude mice bearing high-metastasis human ovarian cancer cell line HO-8910PM. [Methods] Nude mice were randomly divided into 6 groups：tumor-bearing control group（group A）;different concentrations of Rg3 groups：2.Smg/kg（group B）,5mg/kg （group C） and 10mg/kg（group D）;Rg3 and cisplatin group（group E）;cisplatin group（group F）. The variantions of IL-2,INF-γ,nm23,VEGF and PCNA in each group were detected. [Results]Compared with group A,the serum level of IL-2 and INF-γ in group E（P〈0.05） and group F（P〈0.01） reduced sig- nificantly. The expression of nm23 enhanced in the transplanted tumor tissues of group B（P〈0.05）, group C, D and E （P〈0.01）. The expressions of VEGF and PCNA in transplanted tumor tissues decreased after Rg3 administration. [ Conclusion ] Ginsenoside Rg3 combined with cisplatin have a synergetic anti-tumor effect and toxicity attenuation. Rg3 might play a role of anti-tumor through multiple pathways including increasing the expression of nm23, declining the expression of VEGF and PCNA, etc.

关 键 词：人参皂苷 卵巢肿瘤 裸鼠 顺铂 免疫功能 

分 类 号：R737.31[医药卫生—肿瘤]